神经肌肉超声在局灶性神经病中的成本效益
基于一项前瞻性随机双盲对照试验,从社会视角评估神经肌肉超声(NMUS)联合电诊断检查局灶性神经病的成本效益。结果显示,NMUS组平均获得0.079 QALY,平均成本37美元,增量成本效益比(ICER)为每QALY 463美元,低于50000美元/QALY的支付意愿阈值。结论认为NMUS联合电诊断检查具有成本效益。
要点
- NMUS联合电诊断检查局灶性神经病可改善6个月临床结局。
- ICER为463美元/QALY,远低于50000美元/QALY阈值。
- 敏感性分析支持结果稳健,但需更长随访验证。
核心结论
- 从社会视角看,在电诊断检查基础上加用NMUS评估局灶性神经病具有成本效益。
研究设计与样本
- 基于前瞻性随机双盲对照试验的混合试验和模型成本效益分析,从社会视角进行。
- 从36项简表健康调查中提取QALY,成本基于Medicare支付费率。
主要发现
- NMUS相关的平均健康结局为0.079 QALY,平均成本为37美元。
- ICER为每QALY 463美元,低于每QALY 50000美元的支付意愿阈值。
- 结果在所有敏感性分析中保持稳健。
关键数值与推荐
- 增量成本效益比(ICER)为主要结局,支付意愿阈值为每QALY 50000美元。
- NMUS平均成本37美元,平均健康结局0.079 QALY,ICER为463美元/QALY。
临床怎么用
- 在评估局灶性神经病时,可考虑在电诊断检查基础上加用NMUS以提高成本效益。
局限性
- 需要更长随访并纳入总医疗利用的研究来进一步量化NMUS的价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the cost-effectiveness of neuromuscular ultrasound (NMUS) for the evaluation of focal neuropathies. METHODS: A prior prospective, randomized, double-blind controlled trial demonstrated that NMUS, when added to electrodiagnostic testing, resulted in improved clinical outcomes after 6 months of follow-up. From this study, we abstracted quality-adjusted life-years (QALYs) from the 36-item Short Form Health Survey and entered this health-utility estimate into a mixed trial and model-based cost-effectiveness analysis from the societal perspective. Costs of intervention (NMUS) were estimated from Medicare payment rates for Current Procedural Terminology codes. Health care use was otherwise estimated to be equal, but sensitivity analyses further examined this and other key assumptions. Incremental cost-effectiveness ratio (ICER) was used as the primary outcome with a willingness-to-pay threshold of $50,000 per QALY. RESULTS: The predicted mean health outcome associated with use of NMUS was 0.079 QALY, and the mean cost was $37, resulting in an ICER of $463 per QALY. Results and conclusions remained robust across all sensitivity analyses, including variations in time horizon, initial distribution of health states, costs, and effectiveness. CONCLUSIONS: From a societal perspective, the addition of NMUS to electrodiagnostic testing when evaluating a focal neuropathy is cost-effective. A study of longer follow-up incorporating total health care use would further quantify the value of NMUS. CLINICALTRIALSGOV IDENTIFIER: NCT01394822.
引用
- Mandeville R, Wali A, Park C, et al. Cost-effectiveness of neuromuscular ultrasound in focal neuropathies. Neurology. 2019. PMID: 31053668. doi:10.1212/WNL.0000000000007602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。